Share

    


In This Section

Home / Blurb / Discussion List

FDA Approves Alpelisib for Metastatic Breast Cancer

May 28, 2019, 10:19 AM
URL:
On May 24, 2019, the U.S. Food and Drug Administration (FDA) approved alpelisib (Piqray, Novartis Pharmaceuticals Corporation) in combination with fulvestrant for postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.

Read FDA announcement
.

Posted 5/28/2019

Leave a comment